<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>Research | Jensen Lab</title>
  <link rel="stylesheet" href="style.css" />
</head>
<body>
  <header>
    <h1>Jensen Lab</h1>
    <p>UNC Chapel Hill | Department of Medicine â€“ Division of Cardiology</p>
    <nav>
      <ul>
        <li><a href="index.html">Home</a></li>
        <li><a href="research.html">Research</a></li>
        <li><a href="people.html">People</a></li>
        <li><a href="publications.html">Publications</a></li>
        <li><a href="contact.html">Contact</a></li>
      </ul>
    </nav>
  </header>

  <main>
    <section>
      <h2>Research Projects</h2>

      <h3>1. Regulation of Cardiomyocyte Mitochondrial Function by Alpha-1A Adrenergic Receptors</h3>
      <p>
        We investigate the role of alpha-1A adrenergic receptors in regulating mitochondrial metabolism in the heart and their potential as therapeutic targets for heart failure. Our studies suggest that these receptors may protect against cardiometabolic syndrome.
      </p>
      <p><strong>Grant Support:</strong> 2R01 HL140067</p>
      <p><strong>Recent Publications:</strong></p>
      <ul>
        <li><a href="https://pubmed.ncbi.nlm.nih.gov/38362342/" target="_blank">Cardiomyocyte alpha-1A adrenergic receptors mitigate postinfarct remodeling and mortality by constraining necroptosis</a></li>
        <li><a href="https://pubmed.ncbi.nlm.nih.gov/38331556/" target="_blank">The alpha-1A adrenergic receptor regulates mitochondrial oxidative metabolism in the mouse heart</a></li>
        <li><a href="https://pubmed.ncbi.nlm.nih.gov/35170492/" target="_blank">Adrenergic receptor regulation of mitochondrial function in cardiomyocytes</a></li>
        <li><a href="https://pubmed.ncbi.nlm.nih.gov/33275531/" target="_blank">Cardiac alpha-1A adrenergic receptors: emerging protective roles in cardiovascular diseases</a></li>
      </ul>

      <h3>2. Cardiotoxicity of Targeted Cancer Therapies</h3>
      <p>
        We study the cardiovascular side effects of targeted cancer therapies, particularly kinase inhibitors, aiming to understand mechanisms of cardiotoxicity and improve patient outcomes.
      </p>
      <p><strong>Grant Support:</strong> R01 HL165294</p>
      <p><strong>Recent Publications:</strong></p>
      <ul>
        <li><a href="https://pubmed.ncbi.nlm.nih.gov/29051215/" target="_blank">Kinome and transcriptome profiling reveal broad and distinct activities of erlotinib, sunitinib, and sorafenib in the mouse heart</a></li>
        <li><a href="https://pubmed.ncbi.nlm.nih.gov/28977680/" target="_blank">Effects of the kinase inhibitor sorafenib on heart, muscle, liver and plasma metabolism</a></li>
        <li><a href="https://pubmed.ncbi.nlm.nih.gov/28640223/" target="_blank">Non-targeted metabolomics analysis of tyrosine kinase inhibitors sunitinib and erlotinib</a></li>
      </ul>

      <h3>3. Adaptive Roles of the Nuclear Receptor ROR-alpha in the Heart</h3>
      <p>
        Our lab explores the cardioprotective functions of ROR-alpha, a ligand-dependent transcription factor involved in mitochondrial function and cardiac hypertrophy regulation.
      </p>
      <p><strong>Recent Publications:</strong></p>
      <ul>
        <li><a href="https://pubmed.ncbi.nlm.nih.gov/34756888/" target="_blank">The nuclear receptor ROR-alpha preserves cardiomyocyte mitochondrial function by regulating caveolin-3-mediated mitophagy</a></li>
        <li><a href="https://pubmed.ncbi.nlm.nih.gov/30387679/" target="_blank">The nuclear receptor ROR-alpha protects against angiotensin II-induced cardiac hypertrophy and heart failure</a></li>
      </ul>

    </section>
  </main>

  <footer>
    <p>
      &copy; 2025 Jensen Lab | UNC Chapel Hill<br>
      Site created by <a href="https://www.linkedin.com/in/kamthoma" target="_blank">Kam Thomas</a>
    </p>
  </footer> 
</body>
</html>
